PTC THERAPEUTICS, INC.
Close on Oct 19, 2026
- Market cap
- $5.66B
- P/E (TTM)
- –
- Dividend yield
- –
About Ptc Therapeutics
Pharmaceutical Preparations, SIC 2834
PTC Therapeutics is a global biopharmaceutical enterprise focused on discovering, developing, and commercializing therapies for children and adults living with rare disorders. Its operations center on treatments for neurological and metabolic conditions, featuring a commercial portfolio that includes Sephience for phenylketonuria, Translarna and Emflaza for Duchenne muscular dystrophy, and Upstaza and Kebilidi for AADC deficiency. It also commercializes Tegsedi and Waylivra in specific regions and partners on Evrysdi for spinal muscular atrophy. The company serves pediatric and adult patients who have unmet medical needs.
The company maintains an international commercial footprint, supplying therapies across various global markets. Its treatments hold regulatory approvals or marketing authorizations across the United States, the European Economic Area, the United Kingdom, Japan, Brazil, Latin America, the Caribbean, and more than 100 countries globally. In addition to commercial assets, it advances a diversified development pipeline spanning splicing and inflammation platforms. The provided text does not disclose the location of its headquarters.
Summary of the business section of Ptc Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- PTC THERAPEUTICS, INC.
- Founded
- 1998
- Headquarters
- Warren, NJ
- Address
- 500 Warren Corporate Center Drive 07059
- Phone
- (908) 222-7000
- Website
- www.ptcbio.com
- Employees
- 991, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst& Young LLP, Iselin, New Jersey
Stock & identifiers
- Ticker
- PTCT
- Exchange
- Nasdaq
- Shares outstanding
- 83M, Jul 29, 2026
- Public float
- $3.35M, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1070081
- CUSIP
- 69366J200
- ISIN
- US69366J2006
- LEI
- 549300UJLWOIWFDGB318
- EIN
- 04-3416587
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Matthew B. Klein | CHIEF EXECUTIVE OFFICER, Director | 383,868 |
| Mark Elliott Boulding | EXEC. VP AND CLO | 106,241 |
| Pierre Gravier | CHIEF FINANCIAL OFFICER | 83,986 |
| Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFICER | 65,662 |
| Christine Marie Utter | SVP, CHIEF ACCOUNTING OFFICER | 70,199 |
| Eric Pauwels | CHIEF BUSINESS OFFICER | 90,977 |
| Lee Scott Golden | EVP & CHIEF MEDICAL OFFICER | 79,115 |
| Michael Schmertzler | Director | 1,460,236 |
| Hege Elisabeth Sollie-Zetlmayer | Director | 46,526 |
| Mary L. Smith | Director | 21,813 |
| Jessica Caroline Chutter | Director | 7,333 |
| Stephanie Okey | Director | 8,000 |
| Glenn Jr Md Steele Phd | Director | 22,500 |
| David P. Southwell | Director | 22,500 |
| Allan Steven Jacobson | Director | 21,451 |
| Emma Reeve | Director | 10,666 |
| Alethia Young | Director | 21,067 |
| Jerome B. Zeldis | Director | 22,500 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Matthew Klein | $23.27M | $41.16M | $3.39M | $125 | $120 |
| FY2024 Matthew Klein | $7.41M | $14.73M | $2.30M | $74 | $91 |
| FY2023 Matthew Klein | $8.94M | $4.77M | $2.40M | $45 | $92 |
| FY2023 Stuart Peltz | $5.66M | -$3.54M | $2.40M | $45 | $92 |
| FY2022 Stuart Peltz | $7.16M | $5.40M | $3.37M | $63 | $89 |
| FY2021 Stuart Peltz | $11.02M | -$4.95M | $4.33M | $65 | $99 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 991 employees and 56 consultants and contractors.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 30, 2019 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Aug 24, 2018 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Apr 20, 2017 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jun 14, 2013 | Listing | Registration of securities on an exchange (Form 8-A) |